Calcium channel blocker use and risk of Parkinson's disease
Identifieur interne : 001E24 ( Main/Exploration ); précédent : 001E23; suivant : 001E25Calcium channel blocker use and risk of Parkinson's disease
Auteurs : Kelly Claire Simon [États-Unis] ; Xiang Gao [États-Unis] ; Honglei Chen [États-Unis] ; Michael A. Schwarzschild [États-Unis] ; Alberto Ascherio [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-09-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Antihypertensive agent, Calcium Channel Blockers (therapeutic use), Calcium antagonist, Female, Humans, Hypertension (drug therapy), Male, Nervous system diseases, Nurses, Parkinson Disease (etiology), Parkinson disease, Parkinson's disease, Proportional Hazards Models, Risk, Risk factor, antihypertensive, calcium channel blockers.
- MESH :
- chemical , therapeutic use : Calcium Channel Blockers.
- drug therapy : Hypertension.
- etiology : Parkinson Disease.
- Female, Humans, Male, Nurses, Proportional Hazards Models, Risk.
Abstract
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow‐Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow‐up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73–1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD. © 2010 Movement Disorder Society
Url:
- https://api.istex.fr/document/1172DDFF7575CC64877E585931CDF909221B5406/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939261
DOI: 10.1002/mds.23191
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002F64
- to stream Istex, to step Curation: 002F64
- to stream Istex, to step Checkpoint: 000B03
- to stream Pmc, to step Corpus: 000104
- to stream Pmc, to step Curation: 000104
- to stream Pmc, to step Checkpoint: 000362
- to stream PubMed, to step Corpus: 001701
- to stream PubMed, to step Curation: 001701
- to stream PubMed, to step Checkpoint: 001A14
- to stream Ncbi, to step Merge: 002D16
- to stream Ncbi, to step Curation: 002D16
- to stream Ncbi, to step Checkpoint: 002D16
- to stream Main, to step Merge: 002260
- to stream PascalFrancis, to step Corpus: 000937
- to stream PascalFrancis, to step Curation: 002382
- to stream PascalFrancis, to step Checkpoint: 000B81
- to stream Main, to step Merge: 002768
- to stream Main, to step Curation: 001E24
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calcium channel blocker use and risk of Parkinson's disease</title><author><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name></author><author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name></author><author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name></author><author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name></author><author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1172DDFF7575CC64877E585931CDF909221B5406</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.23191</idno><idno type="url">https://api.istex.fr/document/1172DDFF7575CC64877E585931CDF909221B5406/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F64</idno><idno type="wicri:Area/Istex/Curation">002F64</idno><idno type="wicri:Area/Istex/Checkpoint">000B03</idno><idno type="wicri:doubleKey">0885-3185:2010:Simon K:calcium:channel:blocker</idno><idno type="wicri:source">PMC</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939261</idno><idno type="RBID">PMC:2939261</idno><idno type="wicri:Area/Pmc/Corpus">000104</idno><idno type="wicri:Area/Pmc/Curation">000104</idno><idno type="wicri:Area/Pmc/Checkpoint">000362</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001701</idno><idno type="wicri:Area/PubMed/Curation">001701</idno><idno type="wicri:Area/PubMed/Checkpoint">001A14</idno><idno type="wicri:Area/Ncbi/Merge">002D16</idno><idno type="wicri:Area/Ncbi/Curation">002D16</idno><idno type="wicri:Area/Ncbi/Checkpoint">002D16</idno><idno type="wicri:doubleKey">0885-3185:2010:Simon K:calcium:channel:blocker</idno><idno type="wicri:Area/Main/Merge">002260</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:10-0446274</idno><idno type="wicri:Area/PascalFrancis/Corpus">000937</idno><idno type="wicri:Area/PascalFrancis/Curation">002382</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000B81</idno><idno type="wicri:doubleKey">0885-3185:2010:Simon K:calcium:channel:blocker</idno><idno type="wicri:Area/Main/Merge">002768</idno><idno type="wicri:Area/Main/Curation">001E24</idno><idno type="wicri:Area/Main/Exploration">001E24</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Calcium channel blocker use and risk of Parkinson's disease</title><author><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-09-15">2010-09-15</date><biblScope unit="vol">25</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1818">1818</biblScope><biblScope unit="page" to="1822">1822</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1172DDFF7575CC64877E585931CDF909221B5406</idno><idno type="DOI">10.1002/mds.23191</idno><idno type="ArticleID">MDS23191</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antihypertensive agent</term><term>Calcium Channel Blockers (therapeutic use)</term><term>Calcium antagonist</term><term>Female</term><term>Humans</term><term>Hypertension (drug therapy)</term><term>Male</term><term>Nervous system diseases</term><term>Nurses</term><term>Parkinson Disease (etiology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Proportional Hazards Models</term><term>Risk</term><term>Risk factor</term><term>antihypertensive</term><term>calcium channel blockers</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Calcium Channel Blockers</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Male</term><term>Nurses</term><term>Proportional Hazards Models</term><term>Risk</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste calcium</term><term>Antihypertenseur</term><term>Facteur risque</term><term>Maladie de Parkinson</term><term>Pathologie du système nerveux</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow‐Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow‐up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73–1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD. © 2010 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Massachusetts</li></region></list><tree><country name="États-Unis"><region name="Massachusetts"><name sortKey="Simon, Kelly Claire" sort="Simon, Kelly Claire" uniqKey="Simon K" first="Kelly Claire" last="Simon">Kelly Claire Simon</name></region><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><name sortKey="Ascherio, Alberto" sort="Ascherio, Alberto" uniqKey="Ascherio A" first="Alberto" last="Ascherio">Alberto Ascherio</name><name sortKey="Chen, Honglei" sort="Chen, Honglei" uniqKey="Chen H" first="Honglei" last="Chen">Honglei Chen</name><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name><name sortKey="Gao, Xiang" sort="Gao, Xiang" uniqKey="Gao X" first="Xiang" last="Gao">Xiang Gao</name><name sortKey="Schwarzschild, Michael A" sort="Schwarzschild, Michael A" uniqKey="Schwarzschild M" first="Michael A." last="Schwarzschild">Michael A. Schwarzschild</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E24 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001E24 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:1172DDFF7575CC64877E585931CDF909221B5406
|texte= Calcium channel blocker use and risk of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |